BCR-ABL Kinase Domain Mutations by PCR

The Imatinib resistance mutation analysis or BCR-ABL1 kinase domain mutation test by PCR is a molecular diagnostic test used to identify specific mutations within the BCR-ABL1 fusion gene associated with resistance to imatinib, a tyrosine kinase inhibitor used in chronic myeloid leukemia (CML) treatment. The test utilizes PCR to amplify and detect mutations in the kinase domain of the BCR-ABL1 gene. Identifying these mutations helps guide treatment decisions, allowing for alternative therapeutic strategies or the use of different TKIs to overcome imatinib resistance and improve patient outcomes in CML.